Our business is driven by dual innovation engines, integrating two proprietary technology platforms: the small molecule drug R&D platform and the bispecific/trispecific antibodies and complex recombinant protein R&D platform. The synergistic empowerment of these two platforms enables us to build a diversified pipeline with global competitiveness and distinct advantages, which includes multiple drug candidates with best-in-class or first-in-class potential.
Our Small-Molecule Drug R&D Platform
We have established a leading small-molecule drug R&D platform that integrates advanced drug stabilization technology, structure-activity relationship screening technology, and AI-aided drug design and development. By applying these advanced technologies, we are able to reduce development risks and timelines, significantly improve the success rate of new drug discovery, and generate patented compounds with superior efficacy, optimized pharmacokinetic properties, and lower incidence of adverse effects. Among them, structure-activity relationship screening, a core methodology in drug discovery, allows us to build quantitative and qualitative models linking molecular structures to biological activities, thereby efficiently predicting and refining lead compounds through both ligand-based and structure-based design approaches. In parallel, we are harnessing AI to transform drug development, combining deep learning and generative models with traditional R&D to enhance efficiency, lower costs, and shorten development cycles. Deep QSAR techniques automatically learn molecular features to generate or select candidates with ideal pharmacological properties, while generative models create entirely new molecular structures tailored to desired activity and drug-like characteristics, opening a new paradigm in drug design. Leveraging this platform, we have developed a portfolio of internationally competitive patented small-molecule drugs and candidates, including Zepsun®, Zepuping, ZG2001, ZG0895, and ZG2273.
Our Bispecific/Trispecific Antibody and Complex Recombinant Protein R&D Platform
Our bispecific/trispecific antibody and complex recombinant protein R&D platform encompasses three proprietary bispecific/trispecific antibody platforms — TriGen, CheckGen and TGen. The TriGen platform enables the development of trispecific antibodies that overcome the structural limitations of conventional Fab segments, allowing molecules to bind three distinct targets with high druggability, stability, clear mechanisms of action, and reduced off-target effects. The CheckGen platform focuses on bispecific antibodies targeting immune checkpoints and is designed to address tumor immune escape by blocking compensatory pathways and thereby improving patient response rates compared with traditional checkpoint inhibitors. The TGen platform is dedicated to novel bispecific antibody molecules against new targets, generating candidates that can be used as monotherapies, in combination with each other, or alongside PD-1/PD-L1 therapies.
Building on the antibody platforms, we are advancing six programs currently in development — including ZG006, ZG005, ZGGS18, ZGGS34, ZGGS15 and ZG016 — reflecting the breadth and depth of our pipeline. Among them, ZG006, ZG005, and ZGGS34 are under development internationally and have received clinical trial approvals in both China and the United States. Both ZG006 and ZG005 have demonstrated encouraging efficacy and safety results in Phase I/II clinical studies for oncology indications, with the potential to become best-in-class therapies. ZGGS34 has advanced into a Phase I clinical trial in China and obtained IND approval the United States, underscoring the global recognition of our innovation and development capabilities.
In addition to antibody innovation, we have also pioneered a complex recombinant protein platform, successfully developing high-barrier dual-chain protein therapies such as Zepuning and Zesuning, which fill critical gaps in the domestic market and provide us with unique competitive advantages.
